Mfolfox6方案联合西妥昔单抗和辛伐他汀治疗K-Ras突变结直肠癌疗效及对预后的影响  

Efficacy and prognosis of Mfolfox6 regimen combined with cetuximab and simvastatin in treatment of K-Ras mutant colorectal cancer

作　　者：王敬东[1] 张庆尧[1] WANG Jingdong;ZHANG Qingyao(Xinhua Hospital Affiliated to Dalian University,Dalian 116021,China)

机构地区：[1]大连大学附属新华医院,辽宁大连116021

出　　处：《陕西医学杂志》2022年第10期1290-1293,共4页Shaanxi Medical Journal

基　　金：吴阶平医学会基金资助项目(320.6750.17172)。

摘　　要：目的:探究对K-Ras突变结直肠癌患者采用Mfolfox6方案联合西妥昔单抗和辛伐他汀进行治疗的临床疗效,并分析患者治疗后生存时长的相关危险因素。方法:将128例K-Ras突变的结直肠癌患者按照随机数表法分为观察组和对照组(各64例)。对照组患者治疗方式为Mfolfox6方案联合西妥昔单抗,观察组在对照组基础上给予辛伐他汀治疗。(1)对两组患者临床疗效进行比较;(2)记录并比较两组患者不良反应的发生情况;(3)比较两组患者治疗后2年内的总体生存率;(4)分析患者治疗后生存时长的相关危险因素。结果:(1)与对照组患者相比,观察组患者完全缓解(CR)、病情稳定(SD)例数较多,病情进展(PR)、部分缓解(PD)例数较少,总体临床疗效显著提高,组间比较差异有统计学意义(均P<0.05);(2)观察组患者不良反应发生率(25.00%)明显低于对照组(42.19%),组间比较差异有统计学意义(P<0.05);(3)与对照组相比,观察组治疗后1年、治疗后2年生存患者均有明显升高,且组间比较差异有统计学意义(P<0.05);(4)患者的平均生存时间与病理分级、腹膜转移以及治疗方案有显著相关性(均P<0.05),病理分级与腹膜转移是患者治疗后生存时间较短的危险因素。结论:采用Mfolfox6方案+西妥昔单抗+辛伐他汀治疗方案能够显著提高K-Ras突变的结直肠癌患者临床疗效,明显降低患者治疗过程中的不良反应发生率,治疗后患者生存率高,延长患者的生存时间。患者病理状况以及是否存在腹膜转移是影响患者预后的主要因素。Objective:To explore the clinical efficacy of Mfolfox6 regimen combined with cetuximab and simvastatin in the treatment of K-Ras mutant colorectal cancer patients,and to analyze the related risk factors of the patients’ survival time after treatment.Methods:A total of 128 patients with K-Ras-mutated colorectal cancer were randomly divided into observation group and control group according to the random number table method,64 cases in each.The patients in the control group were treated with Mfolfox6 regimen combined with cetuximab,and the patients in the observation group were treated with simvastatin on the basis of the control group.The clinical efficacy of the two groups was compared.The occurrence of adverse reactions in the two groups was recorded and compared,and the overall survival rates within 2 years after treatment were compared between the two groups.The risk factors related to the survival time of patients after treatment were analyzed.Results:Compared with the control group,the observation group had more cases of CR and SD,but fewer cases of PR and PD,and the overall clinical efficacy was significantly improved(all P<0.05).The incidence of adverse reactions in the observation group(25.00%) was significantly lower than that(42.19%) in the control group(P<0.05).Compared with the control group,the survival rate of the observation group 1 year and 2 years after treatment was significantly increased(all P<0.05).The average survival time of patients was significantly correlated with pathological grade,peritoneal metastasis and treatment plan(all P<0.05).Pathological grade and peritoneal metastasis were risk factors for shorter survival time after treatment.Conclusion:For colorectal cancer patients with K-Ras mutation,the Mfolfox6 regimen combined with cetuximab and simvastatin treatment regimen can significantly improve the clinical efficacy and significantly reduce the incidence of adverse reactions during treatment.The survival rate of patients after treatment is also significantly improved,prolonging

关 键 词：Mfolfox6方案 西妥昔单抗 辛伐他汀 K-Ras突变结直肠癌 预后 

分 类 号：R735.37[医药卫生—肿瘤]